Sustained reduction in disability with alemtuzumab is associated with durable quality-of-life improvement on SF-36 over 4 years in CARE-MS II patients with RRMS though most were treatment-free after year 1

Affiliation auteursAffiliation ok
TitreSustained reduction in disability with alemtuzumab is associated with durable quality-of-life improvement on SF-36 over 4 years in CARE-MS II patients with RRMS though most were treatment-free after year 1
Type de publicationJournal Article
Year of Publication2015
AuteursR. Gonzalez A, Moreau T., Hartung H.-P, Hupperts R.M, Kita M., Margolin D.H, Kasten L., Giovannoni G., Investigators CARE-MSII
JournalMULTIPLE SCLEROSIS JOURNAL
Volume21
Pagination600-601
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN1352-4585